Wyeth Pharmaceuticals, Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
Wyeth Pharmaceuticals Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
Wockhardt USA | Wockhardt Limited | Medicare Coverage Gap Discount Program violation | 2020 | CMS | $111,824 |
Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
Warner Chilcott PLC | AbbVie | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
UCB Inc. | UCB | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
UCB Inc. | UCB | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $9,893,322 |
Teva Pharmaceuticals, Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | NY-AG | $313,343,793 |
Teva Pharmaceuticals, Inc. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2023 | KY-AG | $71,477,474 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | Controlled Substances Act violation | 2019 | OK-AG | $85,000,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,250,000,000 |
Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | TX-AG | $225,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | FL-AG | $278,826,499 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | RI-AG | $21,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | WV-AG | $83,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $8,200,000 |
Teva Parmaceuticals | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $27,000,000 |
Teva | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2024 | MD-AG | $70,281,867 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | off-label or unapproved promotion of medical products | 2014 | FDA | $56,500,000 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,786,034 |
Serono, S.A. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
Serono Inc. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
Scios Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $91,602,000 |
Sandoz, Inc. | Sandoz Group | HHS civil monetary penalties | 2015 | HHSOIG | $12,640,000 |
Sandoz, Inc. | Sandoz Group | HHS civil monetary penalties | 2011 | HHSOIG | $230,000 |
Purdue Pharma, L.P. | Purdue Pharma | Controlled Substances Act violation | 2015 | NY-AG | $75,000 |
Purdue Pharma | Purdue Pharma | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | $19,500,000 |
Purdue Pharma | Purdue Pharma | Controlled Substances Act violation | 2019 | OK-AG | $270,000,000 |
Purdue Frederick Company, Inc. and Purdue Pharma, L.P. | Purdue Pharma | Controlled Substances Act violation | 2007 | NV-AG | $1,047,787 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2011 | FDA | $14,500,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $60,000,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MA-AG | $375,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $42,900,000 |
Pfizer | Pfizer | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $35,000,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
Otsuka American Pharmaceutical Inc. | Otsuka Pharmaceutical | off-label or unapproved promotion of medical products | 2008 | FDA | $4,000,000 |
Otsuka American Pharmaceutical Inc. | Otsuka Pharmaceutical | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,700,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
Organon | Organon & Co. | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $31,000,000 |
Novo Nordisk Inc. | Novo Holdings A/S | off-label or unapproved promotion of medical products | 2011 | FDA | $25,000,000 |
Novo Nordisk Inc. | Novo Holdings A/S | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,574,209 |
Novo Nordisk Inc. | Novo Holdings A/S | off-label or unapproved promotion of medical products | 2017 | CA-INS | $1,100,000 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $29,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $88,258,694 |
Novartis Pharmaceuticals | Novartis | off-label or unapproved promotion of medical products | 2012 | TX-AG | $6,638,250 |
Mylan Specialty, L.P. | Viatris | off-label or unapproved promotion of medical products | 2013 | MA-AG | $250,000 |
Merck, Sharp & Dohme | Merck | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
Merck Sharp & Dohme Corp. | Merck | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Medicis Pharmaceutical Corporation | Bausch Health | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $9,800,000 |
Medicis Pharmaceutical Corporation | Bausch Health | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,000,000 |
Mallinckrodt LLC | Mallinckrodt | Controlled Substances Act violation | 2017 | DEA | $35,000,000 |
Mallinckrodt | Mallinckrodt | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
Johnson & Johnson | Johnson & Johnson | Controlled Substances Act violation | 2008 | USAO | $511,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $5,000,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2024 | WA-AG | $149,500,000 |
Jazz Pharmaceuticals Inc. | Jazz Pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | USAO | $20,000,000 |
Janssen Pharmaceuticals/Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MA-AG | $15,100,000 |
Janssen Pharmaceuticals | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | WV-AG | $99,000,000 |
Janssen Ortho LLC and Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2014 | MT-AG | $5,900,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $5,641 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $16,215 |
InterMune Inc. | Roche | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
InterMune Inc. | Roche | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
Inspire Pharmaceuticals Inc. | Merck | off-label or unapproved promotion of medical products | 2015 | USAO | $5,900,000 |
Inspire Pharmaceuticals | Merck | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
Indivior plc | Indivior PLC | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Glenmark Pharmaceuticals, Inc. | Glenmark Pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |
GlaxoSmithKline, LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2013 | MD-AG | $15,000,000 |
GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2010 | KY-AG | $3,700,000 |
GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2009 | KY-AG | $661,860 |
Genentech Inc. | Roche | off-label or unapproved promotion of medical products | 2000 | MULTI-AG | $19,000,000 |
Forest Pharmaceuticals Inc. | AbbVie | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Endo Pharmaceuticals | Endo International | Controlled Substances Act violation | 2020 | OK-AG | $8,750,000 |
Endo Pharmaceuticals | Endo International | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $10,000,000 |
Endo International plc | Endo International | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $450,000,000 |
Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. | Endo International | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Endo Health Solutions and Endo Pharmaceuticals | Endo International | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Endo Health Solutions | Endo International | off-label or unapproved promotion of medical products | 2021 | NY-AG | $50,000,000 |
Endo Health Solution | Endo International | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |